NCT03129269Completed
Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment. We also aim to fully characterize the clinical progression of frail cognitively impaired patients presenting AD (Alzheimer Disease) pathology vs those who also present a cognitive impairment but do not have AD pathology.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 344 (actual)
- First submitted
- 2 Mar 2017
- Start date
- 2 Jan 2017
- Primary completion date
- 16 Jun 2024
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Alzheimer disease
- NCT number
- NCT03129269
What you commit to
- Study type: Interventional
- Participants enrolled: 344
- From 2 Jan 2017 to the primary completion date, 16 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Trauma or surgery which may have left ferromagnetic material in the body, including pacemakers
Other illness
- Presence of any pathology or severe clinical or psychological condition that, according to the investigator, might interfere with study results or may expose the participants to additional risks.
- History of neurosurgery or aneurism
- Extension study (Cog-Frail Plus):
Other
- Individuals presenting severe visual or auditory difficulties which may interfere with the completion of neuropsychological and functional assessments.
- Individuals who are robust according to the Fried criteria (0 criteria)
- Individuals who are dependent (Activities of Daily Living (ADL) \<4)
- Individuals who have a major deterioration in global cognitive function (Mini Mental State Examination (MMSE) \<20)
- Subjects deprived of their liberty by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution (subjects in non-assisted living facilities could be recruited);
- Claustrophobia
- Presence of any severe pathology that, according to the investigator, might interfere with study results or may expose the participants to additional risks.
- Subjects deprived of their liberty by administrative or judicial decision, or under guardianship
Who the study is looking for
- Female and male individuals referred to the Toulouse Frailty Clinic with an objective memory impairment (CDR=0.5 or CDR=1)
- Age ≥ 70 years
- At least 1 Fried-criterion
- Informed consent signed by the patient
- Having an informant accompanying or available by phone
- Individuals affiliated to a healthcare scheme.
- \- Willing to be informed in case of a new pathology discovered through medical examination
- Extension study (Cog-Frail Plus):
- COGFRAIL study participants still included in the study and completing their last visit (M 24)
- Having a family member or legal representant to sign the consent form if MMSE score \<20 at the last visit (M24)
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toulouse University Hospital (CHU de Toulouse) Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
Related publications
- Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort.Alzheimers Res Ther · 2026 · PMID 41634843
This page is information, not medical advice. Discuss any trial with your doctor.